Those treated with enoximone also had lower plasma concentration of TnT and GPBB than the control group, whereas clonidine did not reduce the concentration of these markers of myocardial ischaemia. Pharmacological interventions, such as the continuous infusion of the ACE inhibitor enalaprilat, before start of CPB may help to protect the heart against ischaemia/reperfusion injury.
Abstract
Objective-To evaluate whether clonidine, enoximone, and enalaprilat reduce ischaemia-related myocardial cell damage in cardiac surgery. Design-Prospective randomised controlled trial. Setting-Clinical investigation in a cardiac anaesthesia department of a university hospital. Patients-88 consecutive patients undergoing coronary artery bypass surgery. Interventions-After induction of anaesthesia patients continuously received the (2 agonist clonidine (group 1, n = 22), the phosphodiesterase (PDE) III inhibitor enoximone (group 2, n = 22), the angiotensin converting enzyme (ACE) inhibitor enalaprilat (group 3, n = 22), or saline solution as placebo ( control group, n = 22). The infusion was stopped immediately before the start of cardiopulmonary bypass. Main outcome measures-The ST segment was analysed and the activity of creatine kinase isoenzyme MB (CKMB), cardiac troponin T (TnT), and the BB isoenzyme of glycogen phosphorylase (GPBB) were measured before the start of infusion (baseline), after weaning from cardiopulmonary bypass (CPB), at the end of surgery, 5 h after CPB, and on the morning of the first and third postoperative days. Results-Biometric data and time of cross-clamping were not significantly different in the four groups. Changes in the ST segment indicating ischaemia were least common in the enalaprilat group (P < 0.05). Postoperatively, CKMB activity was significantly higher in the clonidine and the control groups. Both new markers of myocardial cell damage increased more after CPB and postoperatively in the control patients (TnT peak: (mean (SD)) 3*99 (0.35) ugIl; GPBB peak: 82 (15) nglml) and the clonidine-treated group (TnT peak: 3*80 (0.3) pgIl; GPBB peak: 85 (14) ng/ml). Enalaprilat-treated patients showed the smallest overall changes in standard (CKMB) and new serological markers of myocardial ischaemia (TnT peak: 0-71 (0.1) pgIl; GPBB peak: 44 (14) nglml).
Conclusions-In patients treated with enalaprilat before CPB, both new, more sensitive markers of ischaemic myocardial tissue damage increased significantly less than in an untreated control group. Those treated with enoximone also had lower plasma concentration of TnT and GPBB than the control group, whereas clonidine did not reduce the concentration of these markers of myocardial ischaemia. Pharmacological interventions, such as the continuous infusion of the ACE inhibitor enalaprilat, before start of CPB may help to protect the heart against ischaemia/reperfusion injury. > 1-5 mg/dl), unstable angina, left ventricular ejection fraction (LVEF) < 40%, left ventricular end diastolic pressure (LVEDP) > 25 mm Hg, and a mean arterial blood pressure (MAP) < 70 mm Hg in a haemodynamically steady state after induction of anaesthesia. Except for aspirin, preoperative medication was continued until the morning of the operation (table 1) .
Preoperatively, the patients were allocated randomly to continuous intravenous infusion of one of the following: group 1 (n = 22) clonidine (0-05 Mg.kg-1.min-l); group 2 (n = 22) enoximone (5 yg.kg-'.min-'); group 3 (n = 22) enalaprilat (0-6 ygkg-'min-l); group 4 (n = 22) saline solution given as placebo (control patients). The infusion was started after induction of anaesthesia and was continued until the start of CPB.
ANAESTHESIA AND CARDIOPULMONARY BYPASS Anaesthesia was induced with midazolam (0 15 mg/kg), fentanyl (5 ,g/kg), and pancuronium (0-1 mg/kg) and maintained by weight-related doses of these agents. The entire procedure of anaesthesia, documentation, and analyses of all data were carried out by anaesthesiologists not involved in the study and blinded to the patient's study group.
Before the start of CPB, 300 U/kg of bovine heparin was given to achieve anticoagulation (activated clotting time > 400s). CPB was performed with a non-pulsatile pump and membrane oxygenators (Sorin 41, Sorin, Turin, Italy). The circuit was primed with 1000 ml of 5% dextrose solution, 1000 ml of Ringer's solution, and 250 ml of 5% albumin. A flow of 2-4 1 min-mM-2 was used and the temperature was kept between 33°C and 34°C. For myocardial protection, 1000 ml of Bretschneider's cardioplegic solution (low sodium (15 mmol/l), no calcium, containing mannitol (20 mmol/l), and buffered with histidine (180 mmol/l)) was given over 5 min by gravity followed by a 200 ml reinfusion after 30 min. Topical myocardial cooling was extensively performed during infusion of cardioplegia by rinsing cold saline solution over the surface of the heart. Within 20 min after the start of CPB, blood in the extracorporeal circuit was concentrated using an ultrafiltration device (haemofilter HF-80, Fresenius, Bad Homburg, Germany) to keep haemoglobin between 8 and 9 g/dl. When necessary, Ringer's solution or packed red blood cells (PRBC) (when haemoglobin was < 8 g/dl) was added to the circuit to maintain the filling volume of the reservoir. During separation from bypass, as much pump blood as was necessary to keep pulmonary capillary wedge pressure (PCWP) > 10 Hg mmg but < 12 mm Hg was infused. After CPB ended, the residual blood of the extracorporeal oxygenation equipment was concentrated using the HF-system, and the autologous blood was retransfused until the end of the operation. Protamine sulphate was given to antagonise the heparin (1:1 ratio) that had been given initially. All patients were operated upon by the same surgical team blinded to the treatment group. (SD) . Demographic data and outcome data (for example, number of patients who needed inotropic support) were tested using the chi- (table 3) . ST segment changes were least common in the enalaprilat-treated patients (P < 0-01). All patients were transferred to a normal ward by the second day and none of the patients died during the study period. All patients were doing well (stable haemodynamics, no ECG changes) when they were discharged from hospital. Infusion of all three substances produced similar reductions in MAP (table 4) . HR decreased in the clonidine group (from 69-6 (5 3) to 60-4 (7 9) min-'), whereas HR in the other groups remained almost unchanged during the infusion period (table 4) . CI was reduced only in the clonidine patients (from 2-78 (0.2) to 2-39 (02) 1min-1Im-2) and increased in the enoximone patients (from 2-51 (03) to 3-19 (03)l1min-1Im-2) (P < 0 05) (table 4).
CKMB activity was similar in all four groups before and after CPB as well at the end of surgery and 5 h after CPB (fig 1) . On the first postoperative day, CKMB was significantly higher in the clonidine (35 1 (4 9) U/1) and the control group (34.2 (5 8) U/1) than in the enoximone (17-1 (3*1) U/1) and enalaprilat patients (7.5 (2 3) U/1, P < 0-001).
Baseline values of plasma TnT were normal in all the groups (< 0 l,ugIl); there were significant differerences between the groups after CPB (fig 2) . At 
Starting from comparable baseline values (<1 ng/ml), GPBB plasma concentrations after CPB did not differ among the treated patients (fig 3) . In the enalaprilat group they remained significantly lower during the entire postbypass and postoperative period (peak 44 (13) ng/ml at the end of surgery) than in the other groups (P < 0 01). Plasma concentrations of GPBB were similar in the clonidinetreated patients (peak 85 (14) ng/ml 5 h after CPB) and the control group (peak 82 (15) ng/ml).
Discussion
Several substances have been claimed to have anti-ischaemic effects in patients undergoing cardiac surgery.'5-'7 The beneficial action of the centrally acting a% adrenoceptor agonist clonidine was attributed to a reduction in sympathomimetic outflow. In an experimental setting, clonidine was shown to be of benefit in avoiding myocardial ischaemia. '4 In patients undergoing CABG, oral pretreatment with clonidine (5,g/kg) reduced the incidence of ischaemic ST segment changes compared with an untreated control group.'7 Clonidine did not provide the myocardium of our patients with much protection from ischaemia: ST segment alterations indicating ischaemia were most often seen in these patients and CKMB plasma concentrations increased after CPB, which was taken to indicate myocardial issue damage.'5 Serial measurements of two other more sensitive markers of myocardial cell damage, TnT and GPBB, were similar in the clonidine and control groups. The increases in TnT plasma concentrations of our control (and clonidine) patients in the postbypass and postoperative periods were similar to those reported by Mair et al who found an increase of up to 3-5 U/I in patients with an "uncomplicated" course after CPB and of more than 3.5 U/I in patients showing ST-segment changes. 4 Hofmann et al reported on three patients undergoing CABG and found a plasma concentration of GPBB of about 50 ng/ml after release of the cross-clamp (that is, the beginning of reperfusion)," which accords with the data of our clonidine, control, and enoximone groups in the postbypass period.
The PDE-III inhibitor enoximone may influence myocardial ischaemia either by its (direct) effects on the cAMP system or (indirectly) by improving coronary (micro) perfusion. In patients in whom ventricular pacing was performed, enoximone increased the angina threshold while the left ventricular stroke work index was maintained. ' cardioprotective effects when they were given before ischaemia. In an experimental setting when myocardial ischaemia was induced by coronary occlusion, enalapril resulted in a preservation of myocardial tissue.'9 When intravenous enalaprilat was given to our patients in the pre-bypass period it significantly reduced ischaemia-related sequelae in the myocardium. ST segment changes were least common and changes in both new markers of (minor) myocardial cell injury (TnT, GPBB) were smallest during the entire postbypass and postoperative period in the group treated with enaliprilat. The mechanisms of the beneficial effects of ACE inhibitors in this situation has not yet been clarified. ACE inhibitors act not only by blocking systemic angiotensin converting enzyme but also by inhibiting tissue ACE." Stimulation of prostacyclin synthesis, increased endothelial production of nitric oxide, and limitation of endothelin production may also contribute to their cardioprotective effects.'8 The beneficial effects of enalaprilat in our study contrast with results in an experimental setting." When various ACE inhibitors were given 10 min before a 25 min period of global ischaemia and during a 30 min period of reperfusion in the isolated rat heart, an improvement in post-ischaemic contractile function and a reduction in cell death was seen only in the groups that had captopril and zofenopril-sulphhydryl added; enalaprilat was not cardioprotective in high concentrations. The authors assumed that only sulphhydryl-containing ACE inhibitors (not enalaprilat) are effective in limiting ischaemic myocardial tissue damage.
One major problem is that the optimal doses for myocardial protection of the infused substances are not definitely known. We gave 0-05,ug-kg-'*min-' of clonidine continuously by intravenous infusion, a total dose of 307 (26) ,ug. In a study aimed at reducing intraoperative stress, Kulka et al used 2 to 6,g/kg intravenously,34 which is comparable to the dosage in our study. Others Although all the drugs used in this study have long pharmacological half lives, we gave them by continuous intravenous administration because this route is associated with fewer negative haemodynamic sequelae. Data from the present study do not show whether different plasma concentrations of the three drugs at the end of the ischaemic period (in the reperfusion period after release of aortic cross-clamp) influenced myocardial cell damage. Because all of them have a half-life greater than 60 min, all seem to be present in the reperfusion period and thus may have influenced post-CPB myocardial ischaemia in this way as well.
It is difficult to compare the results of our study with those of other studies focusing on myocardial ischaemia in cardiac surgery patients because of the widely varying study conditions. Different methods of myocardial preservation (for example, different cardioplegic solutions), different patient populations (for example, valve versusCABG patients, stable versus unstable angina), different degrees of hypothermia, varying periods of aortic cross-clamping, and different technique of anaesthesia may influence the degree of ischaemia-related myocardial cell damage.
It was not the aim of the present study to determine whether drugs can help to improve outcome in cardiac surgery. This would require comprehensive multicentre studies.
However, the importance of intraoperative ischaemia in these patients has recently been emphasised.38 According to Mangano et al the positive predictive value of intraoperative ischaemia was better than that of postoperative ischaemia (33% v 26%) as was the specificity (79% v 64%)39--thus intraoperative ischaemia may indicate a higher risk than postoperative ischaemia. The present study was performed in elective coronary artery bypass grafting. The beneficial cardioprotective effects may be of particular interest in emergency or complicated surgical procedures with expected prolonged ischaemic periods and patients at higher risk of myocardial ischaemia.
In summary, one major therapeutic aim in cardiac surgery should certainly be the prevention of myocardial ischaemia. New markers of myocardial ischaemia such as cardiac troponin (TnT) and the isoenzyme BB of the glycogen phosphorylase (GPBB) give us a better way of monitoring our attempts at cardioprotection. Intravenous enalaprilat given in the preischaemic period resulted in the smallest overall increase in these markers of ischaemia after CPB, whereas clonidine had no benefical cardioprotective effects and cannot be recommended for this purpose in cardiac surgery. Our results should prompt further investigations to assess the exact role of ACE inhibitors in reducing myocardial ischaemia in cardiac surgery patients.
IMAGES IN CARDIOLOGY
3D construction from spiral CT scanning of pericardial calcification (A) (B)
A 63 year old woman presented with tiredness and ankle swelling and was found to have systemic venous congestion. Her anterior-posterior and lateral (A) chest x rays showed a rim of calcification mainly affecting the inferior part of the pericardium and the diagnosis of calcific constrictive pericarditis was subsequently made. Her condition gradually worsened despite treatment with diuretics, and surgery was considered. A preoperative spiral computed tomograph (B) with a 3D reconstruction shows that the pericardial calcification is more extensive than suggested by the x rays. Calcification involved the pulmonary arteries and the whole of the inferior and posterior parts of the pericardium. This information is helpful to the surgeons in their approaches to pericardiectomy.
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